View Future GrowthWORK Medical Technology Group 과거 순이익 실적과거 기준 점검 0/6WORK Medical Technology Group 의 수입은 연평균 -72.4%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 14.8%의 비율로 증가했습니다. 매출은 연평균 39%의 비율로 감소해 왔습니다.핵심 정보-72.38%순이익 성장률n/a주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.90%매출 성장률-38.96%자기자본이익률-5.67%순이익률-10.89%최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트Reported Earnings • Feb 01Full year 2025 earnings releasedFull year 2025 results: US$0.037 loss per share. Revenue: US$9.85m (down 14% from FY 2024). Net loss: US$1.07m (loss narrowed 69% from FY 2024).Reported Earnings • Aug 26First half 2025 earnings released: EPS: US$0.001 (vs US$0.018 in 1H 2024)First half 2025 results: EPS: US$0.001 (down from US$0.018 in 1H 2024). Revenue: US$4.54m (down 14% from 1H 2024). Net income: US$13.2k (down 94% from 1H 2024). Profit margin: 0.3% (down from 4.3% in 1H 2024). The decrease in margin was driven by lower revenue.모든 업데이트 보기Recent updates공고 • Feb 11WORK Medical Technology Group LTD, Annual General Meeting, Feb 25, 2026WORK Medical Technology Group LTD, Annual General Meeting, Feb 25, 2026, at 09:30 China Standard Time. Location: floor 23, no. 2 tonghuinan road, xiaoshan district, zhejiang province, hangzhou ChinaReported Earnings • Feb 01Full year 2025 earnings releasedFull year 2025 results: US$0.037 loss per share. Revenue: US$9.85m (down 14% from FY 2024). Net loss: US$1.07m (loss narrowed 69% from FY 2024).분석 기사 • Jan 09Revenues Working Against WORK Medical Technology Group LTD's (NASDAQ:WOK) Share Price Following 100% DiveWORK Medical Technology Group LTD ( NASDAQ:WOK ) shareholders that were waiting for something to happen have been dealt...공고 • Jan 01Hunan Saitumofei Co., Ltd Obtains Manufacturing Approval for Its Ai-Automated Blood Cellorphology AnalyzerWORK Medical Technology Group LTD through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co. Ltd. and its subsidiaries in China, announced that its subsidiary, Hunan Saitumofei Co. Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence ("AI")-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical's research and development strategy and is expected to position the Company's new AI-driven device as a key growth catalyst. The analyzer consists of a main unit and embedded analysis software. The main unit integrates an optical imaging system, sample-handling module, barcode scanner, automatic oil-immersion unit, control board, and protective housing. It performs white blood cell differential counts on human blood smears and quantifies morphology parameters of red blood cells and platelets, supporting clinicians in cell morphology screening. Powered by advanced AI automation, the analyzer combines high-speed digital imaging, deep-learning algorithms, and a fully automated workflow to identify, pre-classify, and describe the morphology of white blood cells, red blood cells, and platelets in peripheral blood smears. The analyzer, scheduled to begin manufacturing in the first half of 2026, is designed to enhance efficiency, consistency, and accuracy in microscopic examinations while reducing manual workload and operational costs.분석 기사 • Nov 15Why Investors Shouldn't Be Surprised By WORK Medical Technology Group LTD's (NASDAQ:WOK) 26% Share Price PlungeUnfortunately for some shareholders, the WORK Medical Technology Group LTD ( NASDAQ:WOK ) share price has dived 26% in...공고 • Oct 15WORK Medical Technology Group LTD Announces Receipt of Delisting Determination Letter from NasdaqWORK Medical Technology Group LTD announced that the Company received a determination letter, dated October 9, 2025 (the “Letter”), from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company of Nasdaq’s determination to delist the Company’s Class A ordinary shares from The Nasdaq Capital Market, because the Company’s Class A ordinary shares had a closing bid price of $0.10 or less for ten consecutive trading days ending October 8, 2025, which triggered a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii). Pursuant to the Letter, unless the Company requests an appeal, trading of the Company’s Class A ordinary shares will be suspended at the opening of business on October 20, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq. The Company has the right to request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal this determination, with such request due by October 16, 2025. A request for a hearing will stay the suspension of the Company’s securities pending the Panel’s decision. The Company plans to appeal the determination to the Panel on or before October 16, 2025. The Company will consider all available options to regain compliance with the Nasdaq Listing Rules for continued listing on Nasdaq, including, if appropriate, implementing a reverse share split.분석 기사 • Sep 26The Market Doesn't Like What It Sees From WORK Medical Technology Group LTD's (NASDAQ:WOK) Revenues Yet As Shares Tumble 89%The WORK Medical Technology Group LTD ( NASDAQ:WOK ) share price has fared very poorly over the last month, falling by...공고 • Sep 26WORK Medical Technology Group LTD has filed a Follow-on Equity Offering.WORK Medical Technology Group LTD has filed a Follow-on Equity Offering. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 22,055,096 Price\Range: $0.075 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 16,944,238 Transaction Features: Registered Direct OfferingNew Risk • Sep 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 82% per year over the past 5 years. Shareholders have been substantially diluted in the past year (320% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$55.9m market cap).Reported Earnings • Aug 26First half 2025 earnings released: EPS: US$0.001 (vs US$0.018 in 1H 2024)First half 2025 results: EPS: US$0.001 (down from US$0.018 in 1H 2024). Revenue: US$4.54m (down 14% from 1H 2024). Net income: US$13.2k (down 94% from 1H 2024). Profit margin: 0.3% (down from 4.3% in 1H 2024). The decrease in margin was driven by lower revenue.공고 • May 22WORK Medical Technology Group LTD has completed a Composite Units Offering in the amount of $5.495 million.WORK Medical Technology Group LTD has completed a Composite Units Offering in the amount of $5.495 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 10,000,000 Price\Range: $0.5 Discount Per Security: $0.035 Security Name: Pre-Funded Ordinary Units Security Type: Equity/Derivative Unit Securities Offered: 10,000,000 Price\Range: $0.0495 Discount Per Security: $0.003465분석 기사 • May 06WORK Medical Technology Group LTD's (NASDAQ:WOK) Low P/S No Reason For ExcitementWith a price-to-sales (or "P/S") ratio of 0.6x WORK Medical Technology Group LTD ( NASDAQ:WOK ) may be sending very...Board Change • May 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman & CEO Shuang Wu is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공고 • Apr 13WORK Medical Technology Group Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyWORK Medical Technology Group LTD (“WORK Medical” or the “Company”), announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on April 7, 2025, notifying the Company that it is not in compliance with the minimum bid price requirement set in the Nasdaq Listing Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's Class A ordinary shares for the 30 consecutive business days from February 24, 2025 to April 4, 2025, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until October 6, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company's Class A ordinary shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by October 6, 2025, the Company may be eligible for additional time to regain compliance or may face delisting. The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its Class A ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding ordinary shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.공고 • Feb 02WORK Medical Technology Group LTD announced delayed 20-F filingOn 01/31/2025, WORK Medical Technology Group LTD announced that they will be unable to file their next 20-F by the deadline required by the SEC.New Risk • Jan 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.6% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 66% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Market cap is less than US$100m (US$70.3m market cap).New Risk • Jan 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.6% operating cash flow to total debt). Earnings have declined by 66% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$73.1m market cap).공고 • Jan 17WORK Medical Technology Group LTD, Annual General Meeting, Feb 05, 2025WORK Medical Technology Group LTD, Annual General Meeting, Feb 05, 2025.공고 • Jan 13Work Medical Technology Group Ltd Announces Board and Committee ChangesOn December 30, 2024, Mr. Zhongxuan Li, an independent director of WORK Medical Technology Group LTD resigned from the board of directors and each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as the chairperson of the Nominating and Corporate Governance Committee of the Board, effective December 30, 2024. Mr. Li’s resignation from the Board and the three committees was due to personal reasons. To fill in the vacancy created by the resignation of Mr. Zhongxuan Li, on January 1, 2025, the Company extended a director offer letter to Mr. Zhenguo Wu, who accepted the offer and signed a consent to act as a director of the Company. On January 9, 2025, the Nominating and Corporate Governance Committee of the Board recommended, and the Board ratified, the appointment of Mr. Zhenguo Wu to serve as an independent director of the Company, a member of each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as the chairperson of the Nominating and Corporate Governance Committee, effective as of January 1, 2025. Mr. Wu has legal professional experience. He has been a lawyer at Watson & Band Law Offices since December 2024. From April 2021 to November 2024, he served as the board secretary and general counsel at Xuhang Holdings Ltd. From October 2015 to February 2021, he served as the senior vice president of the investment banking division of Shenwan Hongyuan Securities Underwriting and Sponsoring Co. Ltd. Mr. Wu obtained a bachelor’s degree in English from Tangshan Normal University in 2010 and a master’s degree in law from East China University of Political Science and Law in 2013.Board Change • Sep 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Chairman & CEO Shuang Wu is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Aug 25WORK Medical Technology Group LTD has completed an IPO in the amount of $8 million.WORK Medical Technology Group LTD has completed an IPO in the amount of $8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: $4 Discount Per Security: $0.3매출 및 비용 세부 내역WORK Medical Technology Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:WOK 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 2510-14030 Jun 2510-26031 Mar 2511-48031 Dec 2411-47030 Sep 2412-37030 Jun 2411-25031 Mar 2410-14031 Dec 2312-13030 Sep 231403030 Jun 231814031 Mar 232224031 Dec 222114030 Sep 222014030 Jun 221924031 Mar 221934031 Dec 213354030 Sep 214664030 Sep 2053141양질의 수익: WOK 은(는) 현재 수익성이 없습니다.이익 마진 증가: WOK는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: WOK은 수익성이 없으며 지난 5년 동안 손실이 연평균 72.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 WOK의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: WOK은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(13.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: WOK는 현재 수익성이 없으므로 자본 수익률이 음수(-5.67%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/04 12:32종가2026/08/04 00:00수익2025/09/30연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스WORK Medical Technology Group LTD는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Feb 01Full year 2025 earnings releasedFull year 2025 results: US$0.037 loss per share. Revenue: US$9.85m (down 14% from FY 2024). Net loss: US$1.07m (loss narrowed 69% from FY 2024).
Reported Earnings • Aug 26First half 2025 earnings released: EPS: US$0.001 (vs US$0.018 in 1H 2024)First half 2025 results: EPS: US$0.001 (down from US$0.018 in 1H 2024). Revenue: US$4.54m (down 14% from 1H 2024). Net income: US$13.2k (down 94% from 1H 2024). Profit margin: 0.3% (down from 4.3% in 1H 2024). The decrease in margin was driven by lower revenue.
공고 • Feb 11WORK Medical Technology Group LTD, Annual General Meeting, Feb 25, 2026WORK Medical Technology Group LTD, Annual General Meeting, Feb 25, 2026, at 09:30 China Standard Time. Location: floor 23, no. 2 tonghuinan road, xiaoshan district, zhejiang province, hangzhou China
Reported Earnings • Feb 01Full year 2025 earnings releasedFull year 2025 results: US$0.037 loss per share. Revenue: US$9.85m (down 14% from FY 2024). Net loss: US$1.07m (loss narrowed 69% from FY 2024).
분석 기사 • Jan 09Revenues Working Against WORK Medical Technology Group LTD's (NASDAQ:WOK) Share Price Following 100% DiveWORK Medical Technology Group LTD ( NASDAQ:WOK ) shareholders that were waiting for something to happen have been dealt...
공고 • Jan 01Hunan Saitumofei Co., Ltd Obtains Manufacturing Approval for Its Ai-Automated Blood Cellorphology AnalyzerWORK Medical Technology Group LTD through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co. Ltd. and its subsidiaries in China, announced that its subsidiary, Hunan Saitumofei Co. Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence ("AI")-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical's research and development strategy and is expected to position the Company's new AI-driven device as a key growth catalyst. The analyzer consists of a main unit and embedded analysis software. The main unit integrates an optical imaging system, sample-handling module, barcode scanner, automatic oil-immersion unit, control board, and protective housing. It performs white blood cell differential counts on human blood smears and quantifies morphology parameters of red blood cells and platelets, supporting clinicians in cell morphology screening. Powered by advanced AI automation, the analyzer combines high-speed digital imaging, deep-learning algorithms, and a fully automated workflow to identify, pre-classify, and describe the morphology of white blood cells, red blood cells, and platelets in peripheral blood smears. The analyzer, scheduled to begin manufacturing in the first half of 2026, is designed to enhance efficiency, consistency, and accuracy in microscopic examinations while reducing manual workload and operational costs.
분석 기사 • Nov 15Why Investors Shouldn't Be Surprised By WORK Medical Technology Group LTD's (NASDAQ:WOK) 26% Share Price PlungeUnfortunately for some shareholders, the WORK Medical Technology Group LTD ( NASDAQ:WOK ) share price has dived 26% in...
공고 • Oct 15WORK Medical Technology Group LTD Announces Receipt of Delisting Determination Letter from NasdaqWORK Medical Technology Group LTD announced that the Company received a determination letter, dated October 9, 2025 (the “Letter”), from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company of Nasdaq’s determination to delist the Company’s Class A ordinary shares from The Nasdaq Capital Market, because the Company’s Class A ordinary shares had a closing bid price of $0.10 or less for ten consecutive trading days ending October 8, 2025, which triggered a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii). Pursuant to the Letter, unless the Company requests an appeal, trading of the Company’s Class A ordinary shares will be suspended at the opening of business on October 20, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq. The Company has the right to request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal this determination, with such request due by October 16, 2025. A request for a hearing will stay the suspension of the Company’s securities pending the Panel’s decision. The Company plans to appeal the determination to the Panel on or before October 16, 2025. The Company will consider all available options to regain compliance with the Nasdaq Listing Rules for continued listing on Nasdaq, including, if appropriate, implementing a reverse share split.
분석 기사 • Sep 26The Market Doesn't Like What It Sees From WORK Medical Technology Group LTD's (NASDAQ:WOK) Revenues Yet As Shares Tumble 89%The WORK Medical Technology Group LTD ( NASDAQ:WOK ) share price has fared very poorly over the last month, falling by...
공고 • Sep 26WORK Medical Technology Group LTD has filed a Follow-on Equity Offering.WORK Medical Technology Group LTD has filed a Follow-on Equity Offering. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 22,055,096 Price\Range: $0.075 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 16,944,238 Transaction Features: Registered Direct Offering
New Risk • Sep 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 82% per year over the past 5 years. Shareholders have been substantially diluted in the past year (320% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$55.9m market cap).
Reported Earnings • Aug 26First half 2025 earnings released: EPS: US$0.001 (vs US$0.018 in 1H 2024)First half 2025 results: EPS: US$0.001 (down from US$0.018 in 1H 2024). Revenue: US$4.54m (down 14% from 1H 2024). Net income: US$13.2k (down 94% from 1H 2024). Profit margin: 0.3% (down from 4.3% in 1H 2024). The decrease in margin was driven by lower revenue.
공고 • May 22WORK Medical Technology Group LTD has completed a Composite Units Offering in the amount of $5.495 million.WORK Medical Technology Group LTD has completed a Composite Units Offering in the amount of $5.495 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 10,000,000 Price\Range: $0.5 Discount Per Security: $0.035 Security Name: Pre-Funded Ordinary Units Security Type: Equity/Derivative Unit Securities Offered: 10,000,000 Price\Range: $0.0495 Discount Per Security: $0.003465
분석 기사 • May 06WORK Medical Technology Group LTD's (NASDAQ:WOK) Low P/S No Reason For ExcitementWith a price-to-sales (or "P/S") ratio of 0.6x WORK Medical Technology Group LTD ( NASDAQ:WOK ) may be sending very...
Board Change • May 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman & CEO Shuang Wu is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공고 • Apr 13WORK Medical Technology Group Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyWORK Medical Technology Group LTD (“WORK Medical” or the “Company”), announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on April 7, 2025, notifying the Company that it is not in compliance with the minimum bid price requirement set in the Nasdaq Listing Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's Class A ordinary shares for the 30 consecutive business days from February 24, 2025 to April 4, 2025, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until October 6, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company's Class A ordinary shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by October 6, 2025, the Company may be eligible for additional time to regain compliance or may face delisting. The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its Class A ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding ordinary shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.
공고 • Feb 02WORK Medical Technology Group LTD announced delayed 20-F filingOn 01/31/2025, WORK Medical Technology Group LTD announced that they will be unable to file their next 20-F by the deadline required by the SEC.
New Risk • Jan 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.6% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 66% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Market cap is less than US$100m (US$70.3m market cap).
New Risk • Jan 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.6% operating cash flow to total debt). Earnings have declined by 66% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$73.1m market cap).
공고 • Jan 17WORK Medical Technology Group LTD, Annual General Meeting, Feb 05, 2025WORK Medical Technology Group LTD, Annual General Meeting, Feb 05, 2025.
공고 • Jan 13Work Medical Technology Group Ltd Announces Board and Committee ChangesOn December 30, 2024, Mr. Zhongxuan Li, an independent director of WORK Medical Technology Group LTD resigned from the board of directors and each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as the chairperson of the Nominating and Corporate Governance Committee of the Board, effective December 30, 2024. Mr. Li’s resignation from the Board and the three committees was due to personal reasons. To fill in the vacancy created by the resignation of Mr. Zhongxuan Li, on January 1, 2025, the Company extended a director offer letter to Mr. Zhenguo Wu, who accepted the offer and signed a consent to act as a director of the Company. On January 9, 2025, the Nominating and Corporate Governance Committee of the Board recommended, and the Board ratified, the appointment of Mr. Zhenguo Wu to serve as an independent director of the Company, a member of each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as the chairperson of the Nominating and Corporate Governance Committee, effective as of January 1, 2025. Mr. Wu has legal professional experience. He has been a lawyer at Watson & Band Law Offices since December 2024. From April 2021 to November 2024, he served as the board secretary and general counsel at Xuhang Holdings Ltd. From October 2015 to February 2021, he served as the senior vice president of the investment banking division of Shenwan Hongyuan Securities Underwriting and Sponsoring Co. Ltd. Mr. Wu obtained a bachelor’s degree in English from Tangshan Normal University in 2010 and a master’s degree in law from East China University of Political Science and Law in 2013.
Board Change • Sep 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Chairman & CEO Shuang Wu is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Aug 25WORK Medical Technology Group LTD has completed an IPO in the amount of $8 million.WORK Medical Technology Group LTD has completed an IPO in the amount of $8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: $4 Discount Per Security: $0.3